Aisling Capital
Venture capital · New York, New York, United States
Portfolio collected from the firm’s website, last checked Jul 26, 2026.Raises and exits come from each company’s own SEC and company records.
6Deep-tech portfolio1 active
5Portfolio exitsAcquired or listed
0Raises, 12 monthsLatest: OnKure Therapeutics
23Co-investorsShare a portfolio company
Portfolio · 6 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| BridgeBio Oncology Therapeutics | Biotech | Active | — | — |
| OnKure Therapeutics | Biotech | Public | Oct 21, 2024 | $159.4M |
| Kiniksa Pharmaceuticals | Biotech | Public | Nov 23, 2020 | $5.9M |
| Acelyrin | Biotech | Acquired | — | — |
| Corbus Pharmaceuticals | Biotech | Public | — | — |
| Day One Biopharmaceuticals | Biotech | Acquired | — | — |
Peer ranks
Portfolio size#67
Portfolio exits#40
Raises, 12 months#88
Co-investors#90
Co-investors
- LifeSci Venture PartnersVenture capital2 shared
- Versant VenturesVenture capital2 shared
- Apple Tree PartnersVenture capital1 shared
- Atlas VentureVenture capital1 shared
- Avoro Capital AdvisorsVenture capital1 shared
- Boxer CapitalVenture capital1 shared
- Brookside CapitalVenture capital1 shared
- Clarus VenturesVenture capital1 shared
- Cormorant Asset ManagementVenture capital1 shared
- Frazier Healthcare PartnersVenture capital1 shared
Sectors
- Biotech6
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.